DECLARATION data imminent on a $160M balance sheet: VYD2311 efficacy verdict determines whether a BLA-ready COVID antibody franchise survives PEMGARDA's EUA sunset

Updated 33d ago

Invivyd is a commercial-stage biopharmaceutical company with one approved COVID-19 preventive treatment and a second, unapproved treatment in late-stage development for the same indication.

Invivyd's approved COVID prophylaxis antibody PEMGARDA faces EUA termination by June 2027, making VYD2311, a next-generation neutralizing antibody for broader COVID prevention, the company's survival asset. The thesis resolves on whether DECLARATION Phase 3 data show meaningful efficacy, enabling a BLA submission before cash runs out at the data readout. The principal risk is a single-arm-equivalent reliance on one pivotal trial with no fallback, and PEMGARDA's uncertain BLA conversion path removes the revenue bridge if VYD2311 fails.

Status

Challenged

Conviction

Current Thesis Drivers

FDA aligned: single Phase 2/3 pivotal trial sufficient for BLA
DECLARATION enrollment complete; top-line data imminent
$160M cash covers only through DECLARATION readout
PEMGARDA EUA termination notice issued, effective June 2027

What could change the thesis?

DECLARATION readout: efficacy hit enables BLA, miss ends the company
PEMGARDA BLA conversion: FDA acceptance extends runway, rejection removes bridge
Post-readout financing: capital raise preserves optionality, failure forces wind-down

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

3 programs · 11 catalysts

Stress Test